PSMB1

Proteasome component C5

46,415 patent compounds predicted against PSMB1, 30,984 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL605949	0.54	15/20
SCHEMBL606344	0.51	13/20
SCHEMBL464494	0.56	12/20
SCHEMBL607010	0.56	12/20
SCHEMBL464427	0.55	12/20
SCHEMBL606932	0.53	12/20
SCHEMBL606926	0.52	12/20
SCHEMBL464426	0.51	12/20
SCHEMBL606616	0.51	12/20
SCHEMBL607035	0.61	11/20
SCHEMBL605158	0.59	11/20
SCHEMBL606315	0.59	11/20
SCHEMBL464482	0.55	11/20
SCHEMBL606626	0.54	11/20
SCHEMBL464479	0.54	11/20
SCHEMBL605822	0.54	11/20
SCHEMBL606523	0.53	11/20
SCHEMBL605129	0.52	11/20
SCHEMBL606363	0.52	11/20
SCHEMBL464475	0.52	11/20

Germline variants in PSMB1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full PSMB1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to PSMB1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease	PHASE4	UNKNOWN
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer	PHASE2	COMPLETED
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma	PHASE2	WITHDRAWN
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma	PHASE2	COMPLETED
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors	PHASE2	COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy	PHASE2	NOT_YET_RECRUITING
Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	PHASE2	COMPLETED
Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis	PHASE2	RECRUITING
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma	PHASE1	COMPLETED
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM	PHASE1	WITHDRAWN
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma	PHASE1	COMPLETED
Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery	PHASE1	COMPLETED
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer	PHASE1	COMPLETED
Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	PHASE1	COMPLETED
Characterization of the Changes in the Signalling Pathways During Spinal Cord Injury-induced Skeletal Muscle Atrophy	nan	UNKNOWN
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment	nan	UNKNOWN
Cardiovascular Complications of Carfilzomib Treatment	nan	UNKNOWN
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
The Pathophysiology of Bortezomib Induced Peripheral Neuropathy	nan	UNKNOWN
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS)	nan	UNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Safety and Tolerability of a Nutritional Formula Designed to Aid in Maintenance of Muscle During Periods of Caloric Restriction in Adults	nan	NOT_YET_RECRUITING
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT)	nan	UNKNOWN
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract	nan	UNKNOWN
Establishment of Human Cellular Disease Models for Wilson Disease	nan	COMPLETED
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PSMB1 binder may also engage these)

Protein	Name	Similarity
P18421	—	1.000	P18421 →
Q2TBX6	—	1.000	Q2TBX6 →
O09061	—	1.000	O09061 →
Q9IB83	—	0.999	Q9IB83 →
Q9IB84	—	0.997	Q9IB84 →
Q6DRF3	—	0.996	Q6DRF3 →
P28024	—	0.978	P28024 →
Q9P6U7	—	0.972	Q9P6U7 →
Q7DLR9	—	0.970	Q7DLR9 →
P99026	—	0.969	P99026 →
O23714	—	0.969	O23714 →
P34067	—	0.968	P34067 →
P40307	—	0.968	P40307 →
Q3T108	—	0.966	Q3T108 →
PSMB2	Proteasome Macropain subunit	0.966	landscape →
Q5E9K0	—	0.964	Q5E9K0 →
Q9R1P3	—	0.964	Q9R1P3 →
PSMB4	Proteasome subunit beta type-4	0.963	landscape →
O24633	—	0.960	O24633 →
Q9LST6	—	0.951	Q9LST6 →
Q9XG77	—	0.944	Q9XG77 →
Q2RAK2	—	0.943	Q2RAK2 →
B6JAL5	—	0.942	B6JAL5 →
O80526	—	0.942	O80526 →
Q01217	—	0.941	Q01217 →
Q89WM9	—	0.941	Q89WM9 →
Q9D753	—	0.940	Q9D753 →
Q2QXR8	—	0.940	Q2QXR8 →
Q2QZ86	—	0.940	Q2QZ86 →
B8BM17	—	0.940	B8BM17 →